Patent US4707357A successfully refreshed from Google Patents.
US4707357A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Immunologically active peptides capable of inducing immunization against malaria and genes encoding therefor
Assignee: United States Department of Health and Human Services
•
Filing: 1984-06-26
•
Granted: 1987-11-17
•
Expires: 2004-06-26
Abstract
Abstract An immunologically active substantially pure peptide capable of inducing in a human an immune response which is cross reactive with and protective against infection by a malaria parasite, wherein the peptide contains at least 2 consecutive repeats of a sequence Asn-X-Y-Pro wherein X is Ala or Val and Y is Asn or Asp or a sequence of the formula Thr-Glu-Trp-Z-Pro-Cys-Ser-Val-Thr-Cys-Gly-Asn-Gly wherein Z is Ser or Thr or the formula Lys-Pro-S-T-S-Lys-Leu-Lys-Gln-Pro-U-V-Gly-W-Pro wherein S is Lys or Asn, T is His or Glu, U is Gly or Asn, V is As or Glu, and W is Asn or Gln is disclosed along with DNA sequences and various other genetic materials useful in producing these peptides through biological methods.
Inventors
- 👤 John B. Dame
- 👤 Jackie L. Williams
- 👤 Thomas F. McCutchan
- 👤 Imogene Schneider
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 08:11
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/44; C07K14/445; A; A61; A61P; A61P31/00; A61P31/04; A61P33/00; A61P33/02; C07K16/00; C07K16/18; C07K16/20; C07K16/205; A61K; A61K39/00; Y; Y02; Y02A; Y02A50/00; Y02A50/30; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/29
Claims Analysis
Total Claims: 37
Claim 1
Independent Claim
35 words
An antimalarial immunogenic stimulant comprising an immunogenic carrier and a peptide sequence of between 2 and 1000 consecutive repeats of a sequence Asn-X-Y-Pro, wherein X is Ala or Val and Y is Asn or Asp.
Claim 2
Dependent Claim
35 words
An antimalarial immunogenic stimulant comprising an immunogenic carrier and a peptide sequence of between 2 and 1000 consecutive repeats of a sequence Asn-X-Y-Pro, wherein X is Ala or Val and Y is Asn or Asp.
Claim 3
Dependent Claim
15 words
The stimulant of claim 1, wherein said carrier forms at most 90% of said stimulant.
Claim 4
Dependent Claim
14 words
The stimulant of claim 1, wherein carrier forms at most 40% of said stimulant.
Claim 5
Dependent Claim
18 words
A peptide having a sequence A-B-A-B-A-B-(A) 15 -B-(A) 20 , wherein A represents Asn-Ala-Asn-Pro and B represents Asn-Val-Asp-Pro.
Claim 6
Dependent Claim
18 words
A peptide having a sequence A-B-A-B-A-B-(A) 15 -B-(A) 20 , wherein A represents Asn-Ala-Asn-Pro and B represents Asn-Val-Asp-Pro.
Claim 7
Dependent Claim
75 words
A peptide having a sequence A-B-A-B-A-B-(A) 15 -B-(A) 20 , wherein A represents Asn-Ala-Asn-Pro and B represents Asn-Val-Asp-Pro, wherein said sequence is followed by a peptide segment having a sequence Thr-Glu-Trp-Z-Pro-Cys-Ser-Val-Thr-Cys-Gly-Asn-Gly, wherein Z is Ser or Thr; or is preceded by a peptide segment having a sequence Lys-Pro-S-T-S-Lys-Leu-Lys-Gln-Pro-U-V-Gly-W-Pro, wherein S is Lys or Asn, T is His or Glu, U is Gly or Asn, V is Asp or Glu, and W is Asn or Gln.
Claim 8
Dependent Claim
75 words
A peptide having a sequence A-B-A-B-A-B-(A) 15 -B-(A) 20 , wherein A represents Asn-Ala-Asn-Pro and B represents Asn-Val-Asp-Pro, wherein said sequence is followed by a peptide segment having a sequence Thr-Glu-Trp-Z-Pro-Cys-Ser-Val-Thr-Cys-Gly-Asn-Gly, wherein Z is Ser or Thr; or is preceded by a peptide segment having a sequence Lys-Pro-S-T-S-Lys-Leu-Lys-Gln-Pro-U-V-Gly-W-Pro, wherein S is Lys or Asn, T is His or Glu, U is Gly or Asn, V is Asp or Glu, and W is Asn or Gln.
Claim 9
Dependent Claim
16 words
The peptide of claim 5, wherein said peptide has a sequence Lys-Pro-Lys-His-Lys-Lys-Leu-Lys-Gln-Pro-Gly-Asp-Gly-Asn-Pro-Asp-Pro-Asn-Ala-Asn-Pro-Asn-Val-Asp-Pro-Asn-Ala-Asn-Pro-Asn-Val-Asp-Pro-Asn-Ala-Asn-Pro-Asn-Val-Asp-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Val-Asp-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-As -Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn- Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Lys-Asn-Asn-Gln-Gly-Asn-Gly-Gln-Gly-His-Asn-Met-Pro-Asn-Asp-Pro-Asn-Arg-Asn-Val-Asp Glu-Asn-Ala-Asn-Ala-Asn-Asn-Ala-Val-Lys-Asn-Asn-Asn-Asn-Glu-Glu-Pro-Ser-Asp-Lys-His-Ile-Glu-Gln-Tyr-Leu-Lys-Lys-Ile-Lys-Asn-Ser-Ile-Ser-Thr-Glu-Trp-Ser-Pro-Cys-Ser-Val-Thr-Cys-Gly-Asn-Gly.
Claim 10
Dependent Claim
78 words
A vaccine comprising an antimalarial immunogenic stimulant and a physiologically-compatible medium therefor, wherein said stimulant contains an immunogenic carrier and a peptide sequence Thr-Glu-Trp-Z-Pro-Cys-Ser-Val-Thr-Cys-Gly-Asn-Gly, wherein Z is Ser or Thr, or a peptide sequence Lys-Pro-S-T-S-Lys-Leu-Lys-Gln-Pro-U-V-Gly-W-Pro, wherein S is Lys or Asn, T is His or Glu, U is Gly or Asn, V is Asp or Glu, and W is Asn or Gln, and (b) is present in an amount sufficient to elicit an immune response against Plasmodium falciparum.
Claim 11
Dependent Claim
78 words
A vaccine comprising an antimalarial immunogenic stimulant and a physiologically-compatible medium therefor, wherein said stimulant contains an immunogenic carrier and a peptide sequence Thr-Glu-Trp-Z-Pro-Cys-Ser-Val-Thr-Cys-Gly-Asn-Gly, wherein Z is Ser or Thr, or a peptide sequence Lys-Pro-S-T-S-Lys-Leu-Lys-Gln-Pro-U-V-Gly-W-Pro, wherein S is Lys or Asn, T is His or Glu, U is Gly or Asn, V is Asp or Glu, and W is Asn or Gln, and (b) is present in an amount sufficient to elicit an immune response against Plasmodium falciparum.
Claim 12
Dependent Claim
15 words
The vaccine of claim 7, wherein said carrier forms at most 90% of said peptide.
Claim 13
Dependent Claim
10 words
The vaccine of claim 8, wherein said sequence is Thr-Glu-Trp-Z-Pro-Cys-Ser-Val-Thr-Cys-Gly-Asn-Gly.
Claim 14
Dependent Claim
9 words
The peptide of claim 9 wherein Z is Ser.
Claim 15
Dependent Claim
64 words
The stimulant of claim 1, wherein said carrier is bonded to said sequence by an amide bond formed between a carboxylic acid or amino group of said carrier and an amino or carboxylic acid group of said sequence, or by an ester bond formed between a carboxylic acid or hydroxy group of said carrier and an hydroxy or carboxylic acid group of said sequence.
Claim 16
Dependent Claim
14 words
The stimulant of claim 1, wherein said carrier is a protein or a polysaccharide.
Claim 17
Dependent Claim
17 words
The stimulant of claim 12, wherein said carrier has a molecular weight of from 10,000 to 1,000,000.
Claim 18
Dependent Claim
24 words
The stimulant of claim 12 wherein said carrier is an amphoteric protein and said sequence is bound to the hydrophylic portion of said protein.
Claim 19
Dependent Claim
15 words
The stimulant of claim 1, wherein said carrier is a bacterial cell or a liposome.
Claim 20
Dependent Claim
26 words
A method for inducing immunization against malaria which comprises the step of administering an immunologically effective amount of a stimulant of claim 2 to a human.
Claim 21
Dependent Claim
15 words
The stimulant of claim 1, wherein said carrier forms at most 40% of said stimulant.
Claim 22
Dependent Claim
15 words
The stimulant of claim 1, wherein said carrier form at most 20% of said stimulant.
Claim 23
Dependent Claim
14 words
The stimulant of claim 18, wherein carrier forms up to 50% of said repeats.
Claim 24
Dependent Claim
12 words
The stimulant of claim 1, wherein said malaria parasite is Plasmodium falciparum.
Claim 25
Dependent Claim
59 words
A vaccine comprising an antimalarial immunogenic stimulant and a physiologically-compatible medium therefor, wherein said stimulant (a) contains an immunogenic carrier and between 2 and 1000 consecutive repeats of a sequence Asn-X-Y-Pro, wherein X is Ala or Val and Y is Asn or Asp, and (b) is present in an amount sufficient to elicit an immune response against Plasmodium falciparum.
Claim 26
Dependent Claim
59 words
A vaccine comprising an antimalarial immunogenic stimulant and a physiologically-compatible medium therefor, wherein said stimulant (a) contains an immunogenic carrier and between 2 and 1000 consecutive repeats of a sequence Asn-X-Y-Pro, wherein X is Ala or Val and Y is Asn or Asp, and (b) is present in an amount sufficient to elicit an immune response against Plasmodium falciparum.
Claim 27
Dependent Claim
15 words
The vaccine of claim 21, wherein said carrier forms at most 90% of said stimulant.
Claim 28
Dependent Claim
14 words
The vaccine of claim 7, wherein said immune response is against Plasmodium falciparum sporozoites.
Claim 29
Dependent Claim
22 words
The vaccine of claim 7, wherein said immunogenic carrier is a water-soluble macromolecule ranging in molecular weight between about 10,000 and 1,000,000.
Claim 30
Independent Claim
72 words
A method for inducing immunization against malaria which comprises the step of administering to a human an immunologically effective amount of an antimalarial immunogenic stimulant comprising an immunogenic carrier and a peptide sequence Thr-Glu-Trp-Z-Pro-Cys-Ser-Val-Thr-Cys-Gly-Asn-Gly, wherein Z is Ser or Thr, or a peptide sequence Lys-Pro-S-T-S-Lys-Leu-Lys-Gln-Pro-U-V-Gly-W-Pro, wherein S is Lys or Asn, T is His or Glu, U is Gly or Asn, V is Asp or Glu, and W is Asn or Gln.
Claim 31
Independent Claim
72 words
A method for inducing immunization against malaria which comprises the step of administering to a human an immunologically effective amount of an antimalarial immunogenic stimulant comprising an immunogenic carrier and a peptide sequence Thr-Glu-Trp-Z-Pro-Cys-Ser-Val-Thr-Cys-Gly-Asn-Gly, wherein Z is Ser or Thr, or a peptide sequence Lys-Pro-S-T-S-Lys-Leu-Lys-Gln-Pro-U-V-Gly-W-Pro, wherein S is Lys or Asn, T is His or Glu, U is Gly or Asn, V is Asp or Glu, and W is Asn or Gln.
Claim 32
Dependent Claim
15 words
The method of claim 25, wherein said carrier forms at most 90% of said stimulant.
Claim 33
Dependent Claim
16 words
The method of claim 26, wherein said stimulant consists essentially of said sequence and said carrier.
Claim 34
Dependent Claim
10 words
The method of claim 26, wherein said sequence is Thr-Glu-Trp-Z-Pro-Cys-Ser-Val-Thr-Cys-Gly-Asn-Gly.
Claim 35
Dependent Claim
9 words
The method of claim 28, wherein Z is Ser.
Claim 36
Dependent Claim
28 words
An immunologically active peptide consisting of between 2 and 1000 consecutive repeats of a sequence Asn-X-Y-Pro, wherein X is Ala or Val and Y is Asn or Asp.
Claim 37
Dependent Claim
28 words
An immunologically active peptide consisting of between 2 and 1000 consecutive repeats of a sequence Asn-X-Y-Pro, wherein X is Ala or Val and Y is Asn or Asp.
References Cited (Backward Citations)
US4554101A
Cited
US4466917A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-11-16 | 1991-05-18 | 1991-11-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-11-16 | 1995-05-18 | 1995-11-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-11-16 | 1999-05-18 | 1999-11-17 | $7700.00 | Window Closed / Lapsed |